and Arvinas’s first-generation and now-discontinued AR-degrader bavdegalutamide, shows Halda’s preclinical data. “Stay tuned” for more details on the structure, target and preclinical data ...

School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China ...

Two papers in Nature now reveal that a glue degrader and cancer mutations enable an E3 ligase to recognize the same target protein through a convergent binding mode, which could inform discovery ...

State Key Laboratory of Membrane Biology, School of Pharmaceutical Sciences, Tsinghua-Peking Center for Life Sciences, Key Laboratory of Bioorganic Phosphorous Chemistry and Chemical Biology (Ministry ...

Merck Sharp & Dohme LLC patents report the development of proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase (Von Hippel-Lindau disease tumor suppressor [VHL] ligands) ...

A tree nursery established by members of Sengwer community in efforts to reclaim the degraded Embobut Forest in Elgeyo Marakwet County. The rehabilitation of the degraded Embobut Forest in Elgeyo ...

The software giant’s AR-for-Army project is called the Integrated Visual Augmentation System (IVAS) and began in 2018 using hardware based on Microsoft's now-discontinued HoloLens headsets. It hasn’t ...

Consumer AR glasses could soon become a reality thanks to a breakthrough holographic chip from Swave. Lightweight, low-power, affordable AR glasses have thus far been a distant dream. The best ...

The androgen receptor (AR) on the X chromosome is a central driver in this process, activating genes that govern proliferation and survival. Mutations and amplifications of the AR are closely ...

At the forefront of Nurix's clinical pipeline is NX-5948, a BTK degrader that has demonstrated significant potential in treating Chronic Lymphocytic Leukemia (CLL) and other hematological ...

An Update on the PARP Inhibitor Olaparib in mCRPC Patients: Review of the Phase 2 Results & A First Look at the Phase 3 Study.